ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Clinical trials for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) explained in plain language.
Never miss a new study
Get alerted when new ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) trials appear
Sign up with your email to follow new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for heart patients: experimental drug targets hidden fat risk
Disease control Recruiting nowThis study tests whether adding pelacarsen to standard care (including inclisiran) can safely lower high levels of lipoprotein(a), a genetic risk factor for heart attacks and strokes. About 340 adults with established heart or blood vessel disease will receive either pelacarsen o…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:10 UTC
-
Could a simple pill combo prevent heart attacks and amputations?
Disease control Recruiting nowThis study tests whether a daily polypill (combining several heart medications) plus colchicine can reduce major heart problems, strokes, and limb loss in people with established heart or artery disease. About 7,700 to 10,800 adults aged 45 and older who have had a heart attack, …
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: PHASE3 • Sponsor: Hospital do Coracao • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Could a lower aspirin dose be safer for elderly heart patients?
Disease control Recruiting nowThis study looks at whether a lower dose of aspirin (50 mg daily) works as well as the standard dose (100 mg) to prevent heart attacks and strokes in people aged 60 and older with heart disease. It involves over 5,400 Chinese participants who will be followed for about 6 years. T…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Sponsor: Peking University First Hospital • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New drug aims to cut heart attacks in people with hidden cholesterol risk
Disease control Recruiting nowThis study tests a drug called muvalaplin in about 10,450 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either have had a prior heart attack, stroke, or artery procedure, or are at high risk for a first event. The goal…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
New study aims to predict heart attacks in rheumatoid arthritis patients
Knowledge-focused Recruiting nowThis study is for adults aged 40-79 with rheumatoid arthritis who have at least one heart disease risk factor (like high blood pressure or smoking). It aims to find better ways to detect early signs of heart disease using heart scans and blood tests. The goal is to identify high-…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 06:08 UTC
-
Heart scan study targets hidden danger in inherited high cholesterol patients
Knowledge-focused Recruiting nowThis study aims to find how common hidden heart artery blockages are in people with familial hypercholesterolemia (inherited high cholesterol) who have no symptoms. Researchers will use a special CT scan to look for significant blockages in 600 participants. The goal is to better…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC